卖水的首富，重仓医美女王34个亿

Core Insights - The article discusses a significant investment by Zhong Shanshan, a wealthy entrepreneur, into Jinbo Biotechnology, which is set to receive 2 billion yuan for a 6.24% stake, valuing the company at 32 billion yuan [2][4][12]. Group 1: Investment Details - Jinbo Biotechnology has announced a private placement to raise approximately 2 billion yuan, with shares priced at 278.72 yuan each, representing a discount to the market price [4]. - The funds will primarily be used for the development of a humanized collagen FAST database and product development platform, as well as to supplement working capital [7][8]. - The total investment for the humanized collagen project is estimated at 1.26 billion yuan, with plans for land acquisition and construction of facilities over a three-year period [7]. Group 2: Company Performance and Market Position - Jinbo's projected revenue for 2024 is 1.443 billion yuan, with a profit of 732 million yuan, indicating a high static price-to-earnings ratio at the 32 billion yuan valuation [7]. - The company specializes in recombinant collagen, a high-performance biomaterial with applications in medical fields, including wound healing and tissue engineering [9][10]. - Jinbo's flagship product, a wrinkle-reducing injection called "Wei Yimei," has achieved significant sales, with over 200,000 units sold and a gross margin of 95% [17][19]. Group 3: Strategic Partnerships and Future Prospects - Zhong Shanshan's investment is expected to enhance Jinbo's operational management and market reach, leveraging his extensive experience in the medical commercialization sector [13][20]. - The collaboration with Yang Xia, the founder of Jinbo, is anticipated to open new avenues for the company's collagen products beyond the medical aesthetics market [19][20]. - Jinbo holds all three existing licenses for recombinant humanized collagen in China, providing a competitive edge in a high-risk, strictly regulated market [19].